NasdaqGS:ACADBiotechs
Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?
Acadia Pharmaceuticals has received European Commission marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older across the European Union, Iceland, Liechtenstein, and Norway, based on Phase 3 LAVENDER data showing statistically significant and clinically meaningful improvements on key clinical scales.
This approval makes DAYBU the first and only authorized therapy for Rett syndrome in the EU, potentially opening a new...